ID   KHYG-1
AC   CVCL_2976
SY   KHYG1; KHYG
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   cancercelllines; CVCL_2976
DR   Cell_Model_Passport; SIDM01661
DR   Cosmic; 1534877
DR   Cosmic; 1542070
DR   Cosmic; 2025323
DR   Cosmic; 2390214
DR   Cosmic; 2785203
DR   DepMap; ACH-001100
DR   DSMZ; ACC-725
DR   DSMZCellDive; ACC-725
DR   GEO; GSM472000
DR   IARC_TP53; 13193
DR   JCRB; JCRB0156
DR   JCRB; NIHS0226
DR   Lonza; 733
DR   Wikidata; Q54899912
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=10803505;
RX   PubMed=10803526;
RX   PubMed=16827800;
RX   PubMed=19194464;
RX   PubMed=21052088;
RX   PubMed=25586472;
RX   PubMed=31160637;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: IL2 dependent.
CC   Doubling time: 24-48 hours (PubMed=10803526); ~30-40 hours (DSMZ=ACC-725); ~54 hours (Note=Lot 11012010), ~30 hours (Note=Lots 07242006 and 11202015), ~25 hours (Note=Lot 10182016) (JCRB=JCRB0156).
CC   HLA typing: A*11:01:01,24:02:01; B*35:01:01,54:01:01; C*01:02:01,03:03:01; DPA1*02:01:01,02:01:01; DPB1*19:01,14:01:01; DQA1*01:03:01,01:03:01; DRA*01:01:01,01:02:02; DRB1*08:03:02,11:01:01 (DSMZCellDive=ACC-725).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (DepMap=ACH-001100).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=10803526; DepMap=ACH-001100).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0226; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ=ACC-725; JCRB=JCRB0156
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,13
ST   D16S539: 9
ST   D18S51: 13,18
ST   D19S433: 13,14
ST   D21S11: 30,32.2
ST   D2S1338: 17,19
ST   D3S1358: 15,16
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,13
ST   Penta E: 5
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 27
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=10803526; DOI=10.1038/sj.leu.2401769;
RA   Yagita M., Huang C.L., Umehara H., Matsuo Y., Tabata R., Miyake M.,
RA   Konaka Y., Takatsuki K.;
RT   "A novel natural killer cell line (KHYG-1) from a patient with
RT   aggressive natural killer cell leukemia carrying a p53 point
RT   mutation.";
RL   Leukemia 14:922-930(2000).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x;
RA   Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.;
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.,
RA   Klinkebiel D.L., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K.,
RA   Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.;
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
//
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G.,
RA   Greiner T.C., Kucuk C., Deffenbacher K., Vose J.M., Smith L., Au W.Y.,
RA   Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H.,
RA   Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RL   Leukemia 25:348-358(2011).
//
RX   PubMed=25586472; DOI=10.1038/ncomms7025;
RA   Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M.,
RA   Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A.,
RA   Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A.,
RA   Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K.,
RA   de Leval L., McKeithan T.W., Chan W.C.;
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//